Organigram And This Canadian Cannabis Brand Expand In Europe And Beyond
Organigram And This Canadian Cannabis Brand Expand In Europe And Beyond
Germany's recent legislative push in the cannabis sector marks a significant turning point not only for the country but also for the European cannabis landscape.
德國最近在大麻領域的立法舉措不僅標誌着該國的重大轉折點，也是歐洲大麻格局的重大轉折點。
Europe has become more open-minded about medical and recreational marijuana over the recent years, which is why growing number of the North American cannabis operators venturing into the new market comes as no surprise.
近年來，歐洲對醫用和休閒大麻變得更加開放，這就是爲什麼越來越多的北美大麻經營者冒險進入新市場不足爲奇的原因。
The burgeoning European market will be one of many hot topics at Benzinga's fall cannabis event. Hear directly for top executives, investors, policymakers and advocates at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.
蓬勃發展的歐洲市場將成爲Benzinga秋季大麻活動的衆多熱門話題之一。在將於10月8日至9日在芝加哥舉行的第19屆Benzinga大麻資本會議上，直接聽取高層管理人員、投資者、政策制定者和倡導者的意見。點擊此鏈接，立即在價格飆升之前獲取門票。
Organigram Expands Cannabis Supply Network In UK
Organigram擴大了英國的大麻供應網絡
On Tuesday, Toronto-based cannabis giant Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI) announced its second international medical cannabis customer in the UK, Avida Medical, a full-service medical cannabis and specials medicines manufacturing business.
週二，總部位於多倫多的大麻巨頭Organigram Holdings Inc.（納斯達克股票代碼：OGI）（多倫多證券交易所股票代碼：OGI）宣佈了其在英國的第二個國際醫用大麻客戶——Avida Medical，這是一家提供全方位服務的醫用大麻和特殊藥品製造公司。
Subject to the terms of the deal, the company expects to supply 1,700 kilograms of high-quality, indoor-grown dried cannabis flower to Avida Medical in the UK over three years.
根據交易條款，該公司預計將在三年內向英國Avida Medical供應1,700公斤高質量的室內種植幹大麻花。
Tim Emberg, chief commercial officer of Organigram praised the move and the "immense potential of the UK market."
Organigram首席商務官蒂姆·恩伯格對這一舉動以及 “英國市場的巨大潛力” 表示讚賞。
"We are pleased to partner with Avida Medical in the UK, marking yet another exciting milestone for Organigram's expansion into the global market," Emberg said. "Our decision to further expand into this market stems from our commitment to ensuring patients have access to reliable, high-quality medical cannabis offerings."
恩伯格說：“我們很高興與英國Avida Medical合作，這標誌着Organigram向全球市場擴張的又一個激動人心的里程碑。”“我們決定進一步向這個市場擴張，源於我們對確保患者獲得可靠、高質量的醫用大麻產品的承諾。”
See also: Weed Giants Tilray And Curaleaf Ramp Up Presence In Europe, Here's Why
另見：大麻巨頭 Tilray 和 Curaleaf 擴大在歐洲的影響力，原因如下
Ghost Drops, The Canadian Cannabis Brand Expands Globally
Ghost Drops，加拿大大麻品牌向全球擴張
Meanwhile, Canadian cannabis brand Ghost Drops announced an exclusive partnership with SOMAÍ Group, an international cannabinoid biopharma company with distribution channels.
同時，加拿大大麻品牌Ghost Drops宣佈與擁有分銷渠道的國際大麻素生物製藥公司索邁集團建立獨家合作伙伴關係。
Under the supply and distribution deal, Ghost Drops-branded products will initially be rolled out across Europe, the United Kingdom and Australia.
根據供應和分銷協議，Ghost Drops品牌的產品最初將在歐洲、英國和澳大利亞推出。
The agreement positions the company to capture market share in cannabis markets across Europe and internationally.
該協議使該公司能夠佔領歐洲和國際大麻市場的市場份額。
"Together, SOMAÍ Group and Ghost Drops will introduce European, U.K., and Australian markets to top-tier Canadian cannabis products, bringing quality relief to patients internationally," said Tom Flow, managing director of SOMAÍ Group's subsidiary RPK Biopharma.
索邁集團子公司RPK Biopharma董事總經理湯姆·弗洛表示：“索邁集團和Ghost Drops將共同向歐洲、英國和澳大利亞市場介紹加拿大頂級大麻產品，爲國際患者帶來質量緩解。”
Now read: Cannabis On The Rise In Europe: Why Germany's Legalization Is A Game Changer For The Ecosystem
立即閱讀：大麻在歐洲崛起：爲什麼德國的合法化改變了生態系統的遊戲規則
OGI Price Action
OGI 價格走勢
Organigram's shares traded 2.75% higher at $1.87 per share during the pre-market session on Tuesday morning.
在週二上午的盤前交易中，Organigram的股價上漲了2.75％，至每股1.87美元。
譯文內容由第三人軟體翻譯。